About
Chris has significant oncology research and development experience, including six years as a senior manager at Cambridge-based pharmaceutical company, Vernalis. His principle expertise lies in cancer cell biology and drug discovery. In this field, he has led project teams taking drug targets from inception through to hit identification, lead optimisation and into preclinical studies. Chris holds a PhD from East Carolina University and completed a Post-Doctoral position in the world renowned oncology laboratory of Professor Bert Vogelstein (Johns Hopkins University) where he pioneered the use of X-MAN™ cancer models in high-throughput screening and drug discovery.
Position in the VCSift Database
- • 927 investors hold the Co-Founder and CEO role in VCSift. Chris Torrance is one of them.
- • 141 investors are based in Cambridge, Cambridgeshire, United Kingdom.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Stages
- seed
- Location
- Cambridge, UK
Contact Information
Find more investors like Chris
Search Investors